10-K: Acurx Pharmaceuticals Reports 2024 Results, Highlights Ibezapolstat's Clinical Progress

Sentiment:

Annual Results 17 March 2025 4:05 PM

📋All filings for Acurx Pharmaceuticals, INC

Acurx Pharmaceuticals' 2024 10-K filing details the company's financial status and the advancement of its lead drug candidate, ibezapolstat, through clinical trials for Clostridioides difficile infection (CDI).

Capital raiseOn January 6, 2025, the company entered into a Securities Purchase Agreement with certain institutional investors and Affiliate Investors, pursuant to which the company agreed to issue and sell, in a 2025 January Registered Direct Offering by the company directly to the Investors and to the Affiliate Investors, an aggregate of 2,463,058 shares of common stock, par value $0.001 per share, of the company (consisting of an aggregate of 2,295,570 Shares purchased by the Investors and an aggregate of 167,488 Shares purchased by the Affiliate Investors), at an offering price of $1.015 per share, for aggregate gross proceeds from the Registered Offering of approximately $2.5 million.In a concurrent private placement (the 2025 January Private Placement and together with the January Registered Offering, the Offering), the company agreed to issue to the Investors and to the Affiliate Investors Series E common warrants (the Series E Warrants) to purchase up to an aggregate of 2,463,058 shares of Common Stock (consisting of Series E Warrants to purchase up to 2,295,570 shares of Common Stock issued to the Investors and Series E Warrants to purchase up to 167,488 shares of Common Stock issued to the Affiliate Investors) at an exercise price of $0.90 per share.On March 6, 2025, the company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the company agreed to issue and sell, in a Registered Direct Offering (the March Registered Offering) by the company directly to the investor (i) 2,150,000 shares (the Shares) of common stock (the Common Stock), par value $0.001 per share, of the company, at a purchase price of $0.40 per share and (ii) pre-funded common stock purchase warrants (the March Pre-Funded Warrants) to purchase up to 595,000 shares of Common Stock at a purchase price of $0.3999 per March Pre-Funded Warrant for aggregate gross proceeds of approximately $1.1 million.In a concurrent private placement (the March Private Placement and together with the March Registered Offering, the March Offering), the company agreed to issue to the investor series F common warrants (the Series F Warrants) to purchase up to an aggregate of 8,235,000 shares of Common Stock.

Worse than expectedThe company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.The company believes its existing cash will not be sufficient to meet its anticipated cash requirements for at least 12 months from the issuance of its financial statements for the year ended December 31, 2024.

Summary

Acurx Pharmaceuticals, a late-stage biopharmaceutical company, is focused on developing antibiotics for difficult-to-treat bacterial infections.
The company's lead candidate, ibezapolstat, targets the pol IIIC enzyme in Gram-positive bacteria and is in Phase 3 clinical trial planning.
Phase 2 clinical data showed a 96% clinical cure rate for ibezapolstat in CDI patients.
The company is also developing ACX-375C, an early-stage antibiotic candidate targeting MRSA, VRE, and PRSP.
Acurx reported a net loss of $14.1 million for the year ended December 31, 2024, and $14.6 million for the year ended December 31, 2023.
The company believes its existing cash will not be sufficient to meet its anticipated cash requirements for at least 12 months from the issuance of its financial statements for the year ended December 31, 2024.
The company is pursuing regulatory approval in the EU and plans to initiate activities in Japan, the UK, and Canada.
Acurx has obtained QIDP and Fast Track designations from the FDA for ibezapolstat, providing incentives for its development.
The company is exploring strategic transactions, including partnerships and potential sale or merger opportunities.
The company has a simple and low-cost process of manufacturing which is expected to yield cost of goods of less than 5% of the anticipated retail price.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive clinical results for ibezapolstat and regulatory progress, the company's financial situation and going concern warning temper the overall outlook.

Positives

Ibezapolstat has a novel mechanism of action targeting the pol IIIC enzyme.
Phase 2 data demonstrated a high clinical cure rate and favorable microbiome effects.
The company has QIDP and Fast Track designations from the FDA.
The company has existing patent coverage in major pharmaceutical markets extending to September 2030.
The company has a simple and low-cost process of manufacturing which is expected to yield cost of goods of less than 5% of the anticipated retail price.
The company has received positive written responses from the EMA under its Scientific Advice Procedure that the clinical, non-clinical and CMC information package submitted supports advancement of the ibezapolstat Phase 3 program.

Negatives

The company has incurred significant net losses and expects to continue to do so.
The company believes its existing cash will not be sufficient to meet its anticipated cash requirements for at least 12 months from the issuance of its financial statements for the year ended December 31, 2024.
The company is reliant on the success of ibezapolstat, and failure to commercialize it would harm the business.
The company faces competition from larger and better capitalized companies.
The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.

Risks

The company may need substantial additional funding and may be unable to raise capital when needed.
Clinical trials may not demonstrate safety and efficacy to the satisfaction of regulatory agencies.
The company may be unable to obtain regulatory approval in the United States or foreign jurisdictions.
The company may be involved in lawsuits to protect or enforce its patents.
The price of the company's stock may be volatile, and investors could lose all or part of their investment.
Nasdaq may delist the company's securities from trading on its exchange.
The company's largest stockholders will exercise significant influence over the company.
Cyber incidents or attacks directed at the company could result in information theft, data corruption, operational disruption and/or financial loss.

Future Outlook

The company plans to initiate international Phase 3 clinical trials for ibezapolstat and is pursuing regulatory approval in the EU, with plans to initiate activities in Japan, the UK, and Canada. The company believes its existing cash will not be sufficient to meet its anticipated cash requirements for at least 12 months from the issuance of its financial statements for the year ended December 31, 2024.

Industry Context

The document highlights the urgent need for new antibiotics to combat antimicrobial resistance, as identified by the WHO, CDC, and FDA. The company's focus on priority pathogens aligns with global public health concerns and regulatory incentives.

Comparison to Industry Standards

The document mentions current treatment options for CDI, including vancomycin and fidaxomicin (Dificid), and compares ibezapolstat's clinical cure rate to the historical vancomycin cure rate.
The document also discusses other companies developing investigational antibiotics for CDI, such as Summit Therapeutics (ridinilazole) and Seres Therapeutics, Inc. (VOWST).
The document notes that Merck discontinued bezlotoximab on January 31, 2025.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings.
Employees' job security is tied to the company's ability to secure funding and advance its pipeline.
Patients with CDI could benefit from a new treatment option if ibezapolstat is approved.

Next Steps

Planning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile infection (CDI).

Key Dates

Date	Description
2018-02-05	Acurx acquired worldwide rights to ibezapolstat from GLSynthesis Inc.
2018-12	Received a safe to proceed notification from FDA relating to the commencement of clinical trials and successful completion of clinical trial drug supply suitable to support our Phase 1 clinical trial.
2019-01	FDA approved fast track designation for ibezapolstat for the oral treatment of CDI.
2019-08	Data reported from Phase 1 clinical trial.
2020-08	Terminated enrollment in Phase 2a early and advanced to Phase 2b.
2020-11	Reported top-line data from Phase 2a clinical trial of ibezapolstat to treat patients with CDI.
2021-06-23	Acurx Pharmaceuticals, LLC converted into Acurx Pharmaceuticals, Inc.
2021-06-29	Completed the IPO for net cash proceeds of $14.8 million.
2021-12-03	Commenced enrollment in Phase 2b clinical trial of ibezapolstat in patients with CDI.
2023-11-02	Announced top-line results from the Phase 2b segment of our Phase 2 clinical trial of ibezapolstat in patients with CDI.
2024-02	Obtained small and medium-sized enterprises (SME) designation from the European Medicines Agency.
2024-04-17	Convened an End-of-Phase 2 Meeting with the FDA.
2024-05-15	Announced a successful End-of-Phase 2 Meeting with the FDA, including confirmation of Phase 3 readiness for ibezapolstat for the treatment of C. difficile infection.
2024-12	Received regulatory guidance from the European Medicines Agency confirming acceptability of our Phase 3 clinical trial protocol.
2025-01-06	Suspended the existing ATM program.
2025-01-06	Entered into a Securities Purchase Agreement with certain institutional investors and Affiliate Investors.
2025-02-24	Received a letter from The Nasdaq Stock Market notifying us that for the preceding 31 consecutive business days our common stock did not maintain a minimum closing bid price of $1.00 per share.
2025-03-06	Entered into a Securities Purchase Agreement with an institutional investor.
2025-03-10	The March Offering closed.
2025-08-25	Deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2).

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.